French National Cancer Institute

Organisation

Acronym: INCa
Role: Partner
Country: FR
Address: 52, avenue André Morizet92513 Cedex Boulogne-Billancourt
Website: https://en-www.cancer.fr/

Programme phases

Funding participation

Joint calls funded by this organisation.

Funded projects

Projects linked to this funding organisation.

HAPLO-IMMUNE

RE-VOLU-TION

French National Cancer Institute

Organisation

Programme phases

Funding participation

Funded projects

Approaching recurrence and resistance mechanisms in esophagogastric adenocarcinomas from the prospective MEMORI trial

Patient-derived models for intratumour functional heterogeneity and its implications for personalized medicine

Bispecific antibodies in Lymphoma: Microenvironmental profiling to predict treatment response and uncover immunogenic resistance mechanisms

BRCAddict – Harnessing BRCAness as a therapeutic target in high-risk pediatric solid tumors

Validation of multiparametric models and Circulating and imaging biomarkers to improve Lung cancer EARLY detection.

Circulating Tumor Cells as Biomarker for Minimal Residual Disease in Prostate Cancer

Impact of Dietary Intervention on tumor immunity

Development Of Patient-derived organoid PLatform for Evading Resistances in Lung Cancer

Defeating Recurrence and resistance in AML: Multigenomic Approaches to analyse heterogeneity

Chronic stress and immunosuppression in lung cancer: focus on epigenetic drivers in cancer-associated fibroblasts

Epigenomic Profiling of Liquid Biopsy and Immunotherapy Resistance in Lung Cancer

An integrated approach for epigenetic risk assessment and biomarker development for breast cancer in prospective cohorts / Identifying early epigenetic predictors of breast cancer risk and their etiology determinants

Implementation of (epi)genetic and metabolic networks in the targeting of T-cell prolymphocytic leukemia

Early prediction of efficacy of endocrine therapy in breast cancer: pilot study and validation with 18F Fluoroestradiol (FES) PET/CT

An integrated european platform to conduct translational studies in myelodysplastic syndromes based on the EuroBloodNet infrastructure

Translational Research in Peripheral T-Cell Lymphomas: from characterization to novel targets

Fighting Resistance in CLL

Genetic and cellular intratumor heterogeneity as predictor of chronic lymphocytic leukemia outcome and treatment resistance

Multiparameric Analysis of the Evolution and Progression of Low-Grade Glioma (LGG)

Validation of immune biomarkers predictive of clinical outcome after HLA-haploidentical hematopoietic stem cell transplantation for acute leukemia

Intratumour heterogeneity, clonal selection and metastatic propensity in breast cancer

High resolution project on prognosis and CARE of cancer patients

New technologies for early detection of HLA loss leukemia relapse after allogeneic hematopoietic stem cell transplantation, and identification of relevant risk factors

The role of IMMune OSteoclasts in CANcer – Implications for therapy

Single-cell immunophenotypic and transcriptomic profiling for minimally-invasive detection of early multiple myeloma

Deciphering immune response against glioblastoma to find new targets

Immune oncology Drug Discovery & Decision - Advanced ex Vivo Approach To Accelerate Response prediction for combined therapies in ovarian cancer

Understanding and therapeutically exploiting the immunosuppressive paracrine signalling in the tumour microenvironment of metastatic lesions

Dissecting phenotypic heterogeneity of human melanoma: building a rationale for active immunotherapies overcoming immunologically-induced dedifferentiation.

Advancing Liquid Biopsies for Monitoring and Personalized Treatment of Children with Neuroblastoma

Identification of molecular therapeutic targets and diagnostic/prognostic biomarkers for Malignant Transformation of Osteochondromas

MAppinG adaptatioN Of tripLe negative breast cancer microenvironments to ImmunotherApy

Tackling resistance to immunotherapy in advanced melanomas through the inhibition of oncomiRs by Locked Nucleic Acids

Metabolomic profiles throughout the continuum of colorectal cancer

A randomized placebo controlled phase II study with Metformin in metabolic-unbalanced breast cancer survivors at higher risk for recurrence

Improving immunotherapy of solid tumors by targeting the immunosuppressive tumor microenvironment: from pre-clinical "proof-of-concept" to the development of phase I studies

Comprehensive genomic characterization of upper urinary tract urothelial carcinoma and paired bladder recurrences

New strategies to detect cancers in carriers of mutations in RB1: blood tests based on tumor-educated platelets, or extracellular vesicles.

Employing NGS technology for improved, non-invasive early detection, staging and prediction of progression in lymphoma patients

Predictive models of therapy response in pancreatic neuroendocrine tumors

Genotype matched therapies in intrahepatic cholangiocarcinoma: a multi-pronged strategy for improving efficacy and combating resistance.

Defining Predictive Immunedeterminants of response to neoadjuvant Chemoradiation in Oesophageal adenocarcinoma

Personalized prevention of colorectal neoplasia by use of genetic variability for the prediction of efficacy and toxicity of treatment with COX-2 inhibitors and aspirin

Early Detection of Prostate Cancer by Liquid Biopsies

PROspective VAlidation of Biomarkers in Ewing Sarcoma for personalised translational medicine

Non-invasive prognostic markers for Resected Early-STage NSCLC: role of circulatING and exosomal miRNAs and free circulating DNA

pREdiction of niVOLUmab acTION in metastatic renal cancer patients: Treg function, tumoral access and NK interactions as predictive biomarkers of immunotherapy.

Reaching the heterogeneous vascular landscape of glioblastoma with multifunctional nanomedicines.

Deciphering Epigenetic Biomarkers to Identify Preleukemic Carriers at Risk

Anti-PD1 and Niraparib (PARPi) combination therapy in gynae carcinosarcoma: Identification of response-predictive biomarkers and resistance mechanisms

Intraoperative tumour sequencing for personalized loco-regional drug combination therapy against glioblastoma recurrences

SmartCAR-T - Reprogramming of the tumor microenvironment with modular engineered CAR-T cells to augment the efficacy of immunotherapy

Standardized Profiling of Epigenetic Loci for decentralized ClAssification of Sinonasal Tumors and idEntification of therapy Response markers

TArgeting acute myeloid Leukemia immunosuppressive microEnvironment by combined IDO1 inhibiTion and PD-1 blockadE

Artificial-intelligence-based end-to-end prediction of cancer immunotherapy response

Clinical utility of tumour heterogeneity in triple negative breast cancer and high-grade serous ovarian carcinoma for prediction of therapy response

Early detection of relapses in stage II-III colon cancer patients by following a personalized molecular signature from a blood test: THRuST

Novel Cancer Therapy: Inducing Double-strand DNA Breaks to Foster Tumor Cell Death, Antigenicity and Immunotherapy Response in New Personalized Models

Validation of the impact of genetic aberrations and host genetic variation in childhood acute lymphoblastic leukemia for integration into clinical practice

Integration of genetic biomarkers and early Minimal Residual Disease to improve risk stratification and cure in childhood Acute Lymphoblastic Leukemia

Development of a Comprehensive Risk Prediction Model for BRCA1 and BRCA2 mutation carriers

Targeting ROBOs and SLIT guidance cues in the immunosuppressive stromal context of pancreatic cancer (TRanSLIT)

TRanslational Implementation of Genetic Evidence in the management of MDS

Innovative mRNA vaccine against NSCLC: Designing a platform of targeted polymeric nanoparticles for efficient personalized therapy

CD3 and CD20 lymphocytes infiltration to predict chemosensitivity in patients with triple negative breast cancer

Radiothermal-Driven Immune Activation to Tackle Pancreatic Hypoxic Tumors